Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Yahoo! Finance
Travere Therapeutics, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter ( see the details here Operator: Good day and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference call over to Anne Crotteau. Please go ahead, ma'am. Anne Crotteau: Thanks, Jenny. Good afternoon and welcome to Travere Therapeutics fourth quarter and full year 2023 financial results and corporate update call. Thank you all for joining. Today's call will be led by our President and Chief Executive Officer, Dr. Eric Dube. Eric will be joined in the prepared remarks by Dr. Jula Inrig, our Chief Medical Officer; Peter Heerma, our Chief Commercial Officer; and Chris Cline, our Chief Financial Officer; Dr. Bill Rote, Senior Vice President of Research and Development, will join up for the Q&A session. Before we be
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Travere Therapeutics, Inc. (NASDAQ: TVTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.MarketBeat
- Travere Therapeutics, Inc. (NASDAQ: TVTX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $15.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Here's What Key Metrics Tell Us About Travere (TVTX) Q1 Earnings [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics Reports First Quarter 2024 Financial ResultsGlobeNewswire
TVTX
Earnings
- 5/6/24 - Miss
TVTX
Sec Filings
- 5/6/24 - Form 10-Q
- 5/6/24 - Form 8-K
- 5/1/24 - Form SC
- TVTX's page on the SEC website